Rett syndrome
New RNA editor boasts increased versatility, safety
The “PRECISE” technique reprograms cells in a way that, unlike DNA editors, avoids potentially permanent off-target effects.
New RNA editor boasts increased versatility, safety
New template streamlines sharing clinical trial results
This month’s Going on Trial newsletter explores a new tool for communicating with clinical trial participants and their families, among other drug development news.
New template streamlines sharing clinical trial results
Trials test utility of EEG biomarkers for autism-related conditions
This month’s Going on Trial newsletter dives into an electroencephalography biomarker that could track the efficacy of treatments for dup15q and Angelman syndromes, among other drug development news.
Trials test utility of EEG biomarkers for autism-related conditions
How organ-on-a-chip models can help drug development
This month’s Going on Trial newsletter explores how organ-on-a-chip models could smooth the transition from preclinical to clinical trials, among other drug development news.
How organ-on-a-chip models can help drug development
Going on Trial: Gene therapy for Rett; return to arbaclofen
This month’s newsletter looks at the early safety data from the first gene therapy trial for Rett syndrome, among other drug development news.
Going on Trial: Gene therapy for Rett; return to arbaclofen
The future of autism therapies: A conversation with Lilia Iakoucheva and Derek Hong
If a therapy for autism’s core traits makes it to market, it will likely take one of three forms, the researchers say.
The future of autism therapies: A conversation with Lilia Iakoucheva and Derek Hong
FDA approval of trofinetide may spur further drug development for Rett
The drug, welcomed by patients, might be just the first of many.
FDA approval of trofinetide may spur further drug development for Rett
Debut drug for Rett syndrome at edge of approval
The U.S. Food and Drug Administration plans to make an approval decision on the first-ever drug for girls and women with Rett syndrome by 12 March.
Debut drug for Rett syndrome at edge of approval
Going on Trial: Orphan drugs; CBD; bumetanide
This month’s newsletter takes a close look at the orphan drug program in the United States, several cannabis-based therapies and a secondary analysis of bumetanide, among other new developments in autism-related drug trials.
Biotech downturn hurts companies targeting autism-linked conditions
After a year of intense growth, funding for biotech is in decline. The result is layoffs and program cuts — and maybe some innovation.
Biotech downturn hurts companies targeting autism-linked conditions
Explore more from The Transmitter
Inclusivity committee disbands in protest at Canadian neuroscience institute
The majority of an 11-person committee resigned from the group this week following news that a staff position overseeing equity, diversity and inclusion would not be renewed.
Inclusivity committee disbands in protest at Canadian neuroscience institute
The majority of an 11-person committee resigned from the group this week following news that a staff position overseeing equity, diversity and inclusion would not be renewed.
How to explore your scientific values and develop a vision for your field
As a new professor, I was caught off guard by one part of the job: my role as an evaluator.
How to explore your scientific values and develop a vision for your field
As a new professor, I was caught off guard by one part of the job: my role as an evaluator.
What neuroscientists should know—and what they can do—about changes to BRAIN initiative funding
Many grant proposals submitted to the program in the past year are unlikely to be funded, according to people within the National Institutes of Health. But scientist advocates are reaching out to congressional representatives to try to make changes for 2025.
What neuroscientists should know—and what they can do—about changes to BRAIN initiative funding
Many grant proposals submitted to the program in the past year are unlikely to be funded, according to people within the National Institutes of Health. But scientist advocates are reaching out to congressional representatives to try to make changes for 2025.